Original Research | ||||||||||||
Efficacy and safety of standard dose pioglitazone versus low-dose pioglitazone as an add on treatment in type 2 diabetes mellitus: A randomized controlled trial Allen Joe Rodrigues, Laxminarayana Kamath, Shreya Chokshi, Raveendra K R.
|
How to Cite this Article |
Pubmed Style Rodrigues AJ, Kamath L, Chokshi S, R RK. Efficacy and safety of standard dose pioglitazone versus low-dose pioglitazone as an add on treatment in type 2 diabetes mellitus: A randomized controlled trial. Natl J Physiol Pharm Pharmacol. 2023; 13(3): 536-541. doi:10.5455/njppp.2023.13.07367202230072022 Web Style Rodrigues AJ, Kamath L, Chokshi S, R RK. Efficacy and safety of standard dose pioglitazone versus low-dose pioglitazone as an add on treatment in type 2 diabetes mellitus: A randomized controlled trial. https://www.njppp.com/?mno=89184 [Access: November 02, 2023]. doi:10.5455/njppp.2023.13.07367202230072022 AMA (American Medical Association) Style Rodrigues AJ, Kamath L, Chokshi S, R RK. Efficacy and safety of standard dose pioglitazone versus low-dose pioglitazone as an add on treatment in type 2 diabetes mellitus: A randomized controlled trial. Natl J Physiol Pharm Pharmacol. 2023; 13(3): 536-541. doi:10.5455/njppp.2023.13.07367202230072022 Vancouver/ICMJE Style Rodrigues AJ, Kamath L, Chokshi S, R RK. Efficacy and safety of standard dose pioglitazone versus low-dose pioglitazone as an add on treatment in type 2 diabetes mellitus: A randomized controlled trial. Natl J Physiol Pharm Pharmacol. (2023), [cited November 02, 2023]; 13(3): 536-541. doi:10.5455/njppp.2023.13.07367202230072022 Harvard Style Rodrigues, A. J., Kamath, . L., Chokshi, . S. & R, . R. K. (2023) Efficacy and safety of standard dose pioglitazone versus low-dose pioglitazone as an add on treatment in type 2 diabetes mellitus: A randomized controlled trial. Natl J Physiol Pharm Pharmacol, 13 (3), 536-541. doi:10.5455/njppp.2023.13.07367202230072022 Turabian Style Rodrigues, Allen Joe, Laxminarayana Kamath, Shreya Chokshi, and Raveendra K R. 2023. Efficacy and safety of standard dose pioglitazone versus low-dose pioglitazone as an add on treatment in type 2 diabetes mellitus: A randomized controlled trial. National Journal of Physiology, Pharmacy and Pharmacology, 13 (3), 536-541. doi:10.5455/njppp.2023.13.07367202230072022 Chicago Style Rodrigues, Allen Joe, Laxminarayana Kamath, Shreya Chokshi, and Raveendra K R. "Efficacy and safety of standard dose pioglitazone versus low-dose pioglitazone as an add on treatment in type 2 diabetes mellitus: A randomized controlled trial." National Journal of Physiology, Pharmacy and Pharmacology 13 (2023), 536-541. doi:10.5455/njppp.2023.13.07367202230072022 MLA (The Modern Language Association) Style Rodrigues, Allen Joe, Laxminarayana Kamath, Shreya Chokshi, and Raveendra K R. "Efficacy and safety of standard dose pioglitazone versus low-dose pioglitazone as an add on treatment in type 2 diabetes mellitus: A randomized controlled trial." National Journal of Physiology, Pharmacy and Pharmacology 13.3 (2023), 536-541. Print. doi:10.5455/njppp.2023.13.07367202230072022 APA (American Psychological Association) Style Rodrigues, A. J., Kamath, . L., Chokshi, . S. & R, . R. K. (2023) Efficacy and safety of standard dose pioglitazone versus low-dose pioglitazone as an add on treatment in type 2 diabetes mellitus: A randomized controlled trial. National Journal of Physiology, Pharmacy and Pharmacology, 13 (3), 536-541. doi:10.5455/njppp.2023.13.07367202230072022 |